Effectors of the Type VI Secretion System Have the Potential to Be Modified into Antimicrobial Peptides

Microbiol Spectr. 2023 Aug 17;11(4):e0030823. doi: 10.1128/spectrum.00308-23. Epub 2023 Jul 20.

Abstract

The use of antibiotics has led to the emergence of multidrug-resistant (MDR) bacteria, and there is an urgent need to find alternative treatments to alleviate this pressure. The type VI secretion system (T6SS) is a protein delivery system present in bacterial cells that secretes effectors that participate in bacterial virulence. Given the potential for the transformation of these effectors into antimicrobial peptides (AMPs), we designed T6SS effectors into AMPs that have a membrane-disrupting effect. These effectors kill bacteria by altering the membrane potential and increasing the intracellular reactive oxygen species (ROS) content. Moreover, AMPs also have a significant therapeutic effect both in vivo and in vitro. This finding suggests that it is possible to modify bacterial components of bacteria themselves to create compounds that fight bacteria. IMPORTANCE This study first identified and modified the T6SS effector into positively charged alpha-helical peptides. These peptides have good antibacterial and bactericidal effects on G+ bacteria and G- bacteria. This study broadens the source of AMPs and makes T6SS effectors more useful.

Keywords: T6SS effector; Tsap; anti-inflammation; antimicrobial peptides; multidrug-resistant.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Antimicrobial Peptides
  • Bacteria / metabolism
  • Bacterial Proteins / metabolism
  • Type VI Secretion Systems* / metabolism

Substances

  • Type VI Secretion Systems
  • Bacterial Proteins
  • Antimicrobial Peptides
  • Anti-Bacterial Agents